Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.
Joint Clinical Trials Office
A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, & Clinical Activity Study of IV Administered IO-202 in R/R AML Patients with Monocytic Differentiation & in R/R CMML
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 3, 2022
Phase 1b/2 Open-Label Multicenter, Dose Optimization Clinical Study of Safety, Tolerability, Pharmacokinetic & Pharmacodynamic Profiles of CFI-400945 as a Single Agent or in Combination with Azacitidine or Decitabine in Patients With AML, MDS, or CMML
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 5, 2022
Doxycycline for Emphysema in People Living with HIV
Study Status:
Open to Enrollment
Primary Investigator:
Date: June 9, 2022
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination with Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients with Advanced Solid Tumors
Study Status:
Open to Enrollment
Primary Investigator:
Date: July 28, 2022
A Phase 1, Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of ARX517 in Subjects with Advanced Solid Tumors Resistant or Refractory to Standard Therapies
Study Status:
Open to Enrollment
Primary Investigator:
Date: August 9, 2022
A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Chaperone-mediated Protein Degrader RNK05047 in Subjects with Advanced Solid Tumors (CHAMP-1)
Study Status:
Open to Enrollment
Primary Investigator:
Date: August 17, 2022
Intra-Arterial (IA) Chemotherapy for Newly Diagnosed, Residual, or Recurrent Atypical Choroid Plexus Papilloma (ACPP) and Choroid Plexus Carcinoma (CPC) Prior to Second-Look Surgery
Study Status:
Open to Enrollment
Primary Investigator:
Date: August 17, 2022
Engage & Connect: A novel, neuroscience-informed streamlined psychotherapy for postpartum depression
Study Status:
Open to Enrollment
Primary Investigator:
Date: August 18, 2022
A Multi-phase, Dose-Escalation followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine/Azacitidine Together) vs Subcutaneous Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia or Acute Myeloid Leukemia
Study Status:
Open to Enrollment
Primary Investigator:
Date: September 13, 2022
A Digital Intervention for Post-Stroke Depression and Executive Dysfunction
Study Status:
Open to Enrollment
Primary Investigator:
Date: September 14, 2022